Cefepime in vitro activity against derepressed extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Enterobacter cloacae by a disc diffusion method [5]

Journal of Antimicrobial Chemotherapy

Volumn 48, Issue 2, 2001, Pages 321-322

  Naumiuk, L ^a   Samet, A ^a   Dziemaszkiewicz, E ^a  

^a Public Hospital No 1   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAMASE; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; ENTEROBACTER CLOACAE; ENTEROBACTER INFECTION; IN VITRO STUDY; LETTER; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN;

BACTERIOLOGICAL TECHNIQUES; BETA-LACTAMASES; CEPHALOSPORINS; ENTEROBACTER CLOACAE; HUMANS;

EID: 0034888978     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (6)

1. Comparison of the MICs of cefepime for extended-spectrum β-lactamase-producing and non-extended-spectrum β-lactamase-producing strains of Enterobacter cloacae
2. Extended broad-spectrum β-lactamase conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: Hospital prevalence and susceptibility patterns
3. Detection of extended-spectrum β-lactamase in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes
4. Detection and reporting of organisms producing extended-spectrum β-lactamases: Survey of laboratories in Connecticut
5. Is it important to identify extended-spectrum-beta-lactamase-producing isolates?